MRI contrast developer Epix Pharmaceuticals of Lexington, MA, said that its request for continued listing on the Nasdaq Global Market has been granted.
The ruling by the Nasdaq Listing Qualifications Panel is subject to the condition that Epix file a current report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) by May 11, attesting to its compliance with SEC requirements of maintaining shareholders' equity of at least $10 million or a minimum market value of listed securities of $50 million.
Related Reading
Epix gets FDA OK for Vasovist, December 23, 2008
Epix reduces its workforce, October 23, 2008
Epix to form technology advisory board, August 14, 2008
Epix's Q2 results show boosted revenues, August 7, 2008
Epix secures equity financing, August 5, 2008
Copyright © 2009 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
